Experimental and clinical data have indicated that high levels of SHP2 mRNA correlate with poor progression-free survival and overall survival in lung adenocarcinomas (12) and SHP2 promotes tumor progression in many types of cancer including breast cancer (13). This evidence concerns the gene PTPN11 and cancer.